Puma Biotechnology to Host Conference Call to Discuss Loperamide Prophylaxis to Reduce Neratinib-Related Diarrhea

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, will
host a conference call and slide presentation to discuss preliminary
results of its Phase II study looking at the incidence and severity of
diarrhea in patients with early-stage HER2-positive breast cancer
treated with extended adjuvant neratinib monotherapy and prophylactic
loperamide. The call will be held at 4:15 p.m. EST (1:15 p.m. PST) on
December 21, 2015.

The live call may be accessed by dialing 877-709-8150 for domestic
callers and 201-689-8354 for international callers. Please specify to
the operator that you would like to join the “Puma Biotechnology Update
Call.” A live webcast of the call and presentation slides will be
available online on the investor relations section of the company
website at http://www.pumabiotechnology.com/ir_events.html
and will be archived there for 30 days following the call. Please visit
Puma’s website several minutes prior to the start of the broadcast to
ensure adequate time for any software download that may be necessary.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on
the acquisition, development and commercialization of innovative
products to enhance cancer care. The Company aims to acquire proprietary
rights to these products, by license or otherwise, fund their research
and development and bring the products to market. The Company is
initially focused on the development of PB272 (oral neratinib), a potent
irreversible tyrosine kinase inhibitor, for the treatment of patients
with HER2-positive breast cancer and patients with non-small cell lung
cancer, breast cancer and other solid tumors that have a HER2 mutation.

Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.

Forward-Looking Statements:

This press release contains forward-looking statements that involve
risks and uncertainties that could cause the Company’s actual results to
differ materially from the anticipated results and expectations
expressed in these forward-looking statements. These statements are
based on current expectations, forecasts and assumptions, and actual
outcomes and results could differ materially from these statements due
to a number of factors, which include, but are not limited to, the risk
factors disclosed in the periodic reports filed by the Company with the
Securities and Exchange Commission from time to time. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof. The Company assumes
no obligation to update these forward-looking statements, except as
required by law.

Contacts

Puma Biotechnology, Inc.
Alan H. Auerbach or Mariann Ohanesian, +1
424 248 6500
info@pumabiotechnology.com
ir@pumabiotechnology.com
or
Russo
Partners
Robert Flamm or David Schull, +1 212 845 4226
robert.flamm@russopartnersllc.com
david.schull@russopartnersllc.com